Savosolar signs delivery contract for a solar thermal system to AbSOLAR in Cadaujac, France
Savosolar has signed a delivery contract with AbSOLAR SAS valued at approximately c. EUR 300 thousand for a solar thermal plant delivery in Cadaujac, France. Delivery of this plant will happen during first half of 2021.
Savosolar informed on 23
rd of April, 2020 of winning a pilot project to AbSOLAR and of an exclusivity agreement with AbSOLAR regarding a larger project for greenhouse with a budgetary value of approximately EUR 2.5 million. This delivery contract is for the earlier informed pilot system for AbSOLAR, and it has been awaiting the decision of the renewable energy subsidy.
Nexstim Oyj: Nexstim Has Received Three New NBS System Orders
Nexstim Has Received Three New NBS System Orders
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that it has received three new NBS system orders in December.
One purchase order came from a new neurosurgical customer in Spain. Two other orders came from existing Nexstim system users in Finland and in the United States. Those two orders are for NBS System upgrades meaning that an NBS System with the latest SmartFocus nTMS features will replace the hospital s older NBS system.
Nexstim NBS systems with SmartFocus nTMS are mainly used for neurosurgical diagnostics to provide information on tumour s or on other lesion s location in relation to the essential functions and their connections in the patient s brain. In addition, NBS Systems are used in research and in Europe the systems can also be used for depression and chronic, neuropathic pain therapy.
Share:
Nexstim Has Received Three New NBS System Orders
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that it has received three new NBS system orders in December.
One purchase order came from a new neurosurgical customer in Spain. Two other orders came from existing Nexstim system users in Finland and in the United States. Those two orders are for NBS System upgrades meaning that an NBS System with the latest SmartFocus® nTMS features will replace the hospital s older NBS system.
Nexstim NBS systems with SmartFocus® nTMS are mainly used for neurosurgical diagnostics to provide information on tumour s or on other lesion s location in relation to the essential functions and their connections in the patient s brain. In addition, NBS Systems are used in research and in Europe the systems can also be used for depression and chronic, neuropathic pain therapy.
Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules
Nanoform
Inside information
December 17, 2020 at 7:15 p.m. Finnish time
Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules
Helsinki, Finland – Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc, an innovative drug development company, today announced that they have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis’ CDNF and xCDNF therapies (Parkinson’s disease) using Nanoform’s proprietary biological nanoparticle technology.
Nexstim Oyj: Nexstim Plc Annuls Stock Options Held by the Company
Nexstim Plc Annuls Stock Options Held by the Company
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that its Board of Directors has resolved in its meeting on 15.12.2020 on annulment of in total 3,108 option rights 2016B; in total 65,827 option rights 2016C; in total 33,888 option rights 2018A; and in total 33,888 option rights 2018B which are in the possession of the Company or have been returned to the possession of the Company due to ended employments.
Pursuant to the annulment, no option rights in those plans remain in the possession of the Company. The Board of Directors of the Company also resolved on annulment of all option rights in the stock option plan 2017 which have been returned to the possession of the Company due to an ended employment and resolved on termination of the stock option plan 2017.